RU2004136984A - Применение доцетаксела/доксорубицина/циклофосфамида во вспомогательной терапии рака молочной железы и яичников - Google Patents
Применение доцетаксела/доксорубицина/циклофосфамида во вспомогательной терапии рака молочной железы и яичников Download PDFInfo
- Publication number
- RU2004136984A RU2004136984A RU2004136984/15A RU2004136984A RU2004136984A RU 2004136984 A RU2004136984 A RU 2004136984A RU 2004136984/15 A RU2004136984/15 A RU 2004136984/15A RU 2004136984 A RU2004136984 A RU 2004136984A RU 2004136984 A RU2004136984 A RU 2004136984A
- Authority
- RU
- Russia
- Prior art keywords
- docetaxel
- cyclophosphamide
- doxorubicin
- use according
- breast cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (8)
1. Применение доцетаксела для изготовления лекарственного препарата для лечения метастатического рака молочной железы или яичников путем вспомогательной терапии только в комбинации с доксорубицином и циклофосфамидом, обеспечивающее повышенный коэффициент выживаемости.
2. Применение по п.1, где доцетаксел, доксорубицин и циклофосфамид вводят раздельно.
3. Применение по п.1 для лечения метастатического рака молочной железы.
4. Применение по п.3, где при указанном раке молочной железы ER, PR и/или HER2 сверхэкспрессированы.
5. Применение по п.2, где доцетаксел, доксорубицин и циклофосфамид вводят один раз в каждые 3 недели.
6. Применение по п.2, где доцетаксел вводят в дозе, приблизительно равной 75 мг/м2 на цикл.
7. Применение по п.2, где доксорубицин вводят в дозе, приблизительно равной 50 мг/м2 на цикл.
8. Применение по п.2, где циклофосфамид вводят в дозе, приблизительно равной 500 мг/м2 на цикл.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38085002P | 2002-05-17 | 2002-05-17 | |
| US60/380,850 | 2002-05-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2004136984A true RU2004136984A (ru) | 2005-06-27 |
| RU2321396C2 RU2321396C2 (ru) | 2008-04-10 |
Family
ID=29550025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004136984/15A RU2321396C2 (ru) | 2002-05-17 | 2003-05-15 | Применение доцетаксела/доксорубицина/циклофосфамида во вспомогательной терапии рака молочной железы и яичников |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20040014694A1 (ru) |
| EP (1) | EP1507573A1 (ru) |
| JP (1) | JP4773719B2 (ru) |
| KR (1) | KR20050000544A (ru) |
| CN (1) | CN1652845A (ru) |
| AU (1) | AU2003244646B2 (ru) |
| BR (1) | BR0310026A (ru) |
| CA (1) | CA2486124A1 (ru) |
| CR (1) | CR7575A (ru) |
| EC (1) | ECSP045433A (ru) |
| HR (1) | HRPK20041072B3 (ru) |
| IL (1) | IL165214A0 (ru) |
| MA (1) | MA27417A1 (ru) |
| ME (2) | ME00055B (ru) |
| MX (1) | MXPA04010640A (ru) |
| MY (1) | MY146533A (ru) |
| NO (1) | NO20045370L (ru) |
| NZ (1) | NZ535992A (ru) |
| OA (1) | OA12819A (ru) |
| PA (1) | PA8574001A1 (ru) |
| RS (1) | RS96304A (ru) |
| RU (1) | RU2321396C2 (ru) |
| TN (1) | TNSN04217A1 (ru) |
| TW (1) | TWI374741B (ru) |
| UA (1) | UA81628C2 (ru) |
| UY (1) | UY27812A1 (ru) |
| WO (1) | WO2003097164A1 (ru) |
| ZA (1) | ZA200408549B (ru) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4779971B2 (ja) * | 2003-09-25 | 2011-09-28 | アステラス製薬株式会社 | ヒストンデアセチラーゼ阻害剤とトポイソメラーゼｉｉ阻害剤とからなる抗腫瘍剤 |
| GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| WO2008027988A2 (en) * | 2006-08-31 | 2008-03-06 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation |
| DK2694056T3 (da) * | 2011-04-01 | 2020-01-02 | Astrazeneca Ab | Terapeutisk behandling |
| MY175800A (en) | 2011-11-30 | 2020-07-09 | Astrazeneca Ab | Combination treatment of cancer |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| US20160067182A1 (en) * | 2013-04-09 | 2016-03-10 | Merrimack Pharmaceuticals, Inc. | Methods and compositions for improving outcomes of liposomal chemotherapy |
| WO2015164665A1 (en) | 2014-04-25 | 2015-10-29 | Genentech, Inc. | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
| WO2016005962A2 (en) | 2014-07-11 | 2016-01-14 | Dr. Reddy’S Laboratories Limited | Stable liquid formulations of cyclophosphamide and processes |
| US10849916B2 (en) | 2014-07-11 | 2020-12-01 | Dr. Reddys Laboratories Limited | Stable liquid formulations of cyclophosphamide and its impurities |
| US10238650B2 (en) | 2015-03-06 | 2019-03-26 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
| WO2017011399A1 (en) | 2015-07-13 | 2017-01-19 | Beyondspring Pharmaceuticals, Inc | Plinabulin compositions |
| US20190054019A1 (en) * | 2015-10-22 | 2019-02-21 | Universidade De Santiago De Compostela | Methods for using regulators for increasing the expression or activation of p53 and/or regulators for reducing or inhibiting the expression of p63-alpha, for the treatment of non-alcoholic fatty liver disease (nafld) and/or non-alcoholic steatohepatitis (nash) |
| IL260933B2 (en) | 2016-02-08 | 2023-04-01 | Beyondspring Pharmaceuticals Inc | Preparations containing tocorsol or its analogues |
| US20190177430A1 (en) * | 2016-08-24 | 2019-06-13 | The Wistar Institute Of Anatomy And Biology | Methods of Treating Cancers With Chemotherapy With Reduced Toxicity |
| WO2018067575A1 (en) * | 2016-10-03 | 2018-04-12 | Indiana University Research And Technology Corporation | Combination drug therapy reduces parp-1 related dna repair and increases the efficacy of genotoxic agents |
| CN110431135A (zh) | 2017-01-06 | 2019-11-08 | 大连万春布林医药有限公司 | 微管蛋白结合化合物及其治疗用途 |
| CA3052190A1 (en) * | 2017-02-01 | 2018-08-09 | Beyondspring Pharmaceuticals, Inc. | Method of reducing neutropenia |
| US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
| BR112020014960A2 (pt) | 2018-01-24 | 2020-12-22 | Beyondspring Pharmaceuticals, Inc. | Composição e método para redução de trombocitopenia |
| JP7373170B2 (ja) | 2018-06-22 | 2023-11-02 | オハイオ ステート イノベーション ファウンデーション | ジヒドロオロト酸デヒドロゲナーゼ阻害のための方法及び組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601675B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| MX9102128A (es) | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| US6441026B1 (en) * | 1993-11-08 | 2002-08-27 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
| US5565478A (en) * | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
| US6262054B1 (en) * | 1996-02-01 | 2001-07-17 | Sloan-Kettering Institute Of Cancer Research | Combination therapy method for treating breast cancer using edatrexate |
| US6323205B1 (en) * | 1996-07-17 | 2001-11-27 | Sloan-Kettering Institute For Cancer Research | Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors |
| US6541508B2 (en) * | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| US20020128228A1 (en) * | 2000-12-01 | 2002-09-12 | Wen-Jen Hwu | Compositions and methods for the treatment of cancer |
-
2003
- 2003-05-15 CN CNA038112388A patent/CN1652845A/zh active Pending
- 2003-05-15 ME MEP-2008-163A patent/ME00055B/me unknown
- 2003-05-15 UA UA20041210381A patent/UA81628C2/ru unknown
- 2003-05-15 IL IL16521403A patent/IL165214A0/xx unknown
- 2003-05-15 ME MEP-163/08A patent/MEP16308A/xx unknown
- 2003-05-15 RS YU96304A patent/RS96304A/sr unknown
- 2003-05-15 AU AU2003244646A patent/AU2003244646B2/en not_active Ceased
- 2003-05-15 KR KR10-2004-7018431A patent/KR20050000544A/ko not_active Application Discontinuation
- 2003-05-15 RU RU2004136984/15A patent/RU2321396C2/ru not_active IP Right Cessation
- 2003-05-15 CA CA002486124A patent/CA2486124A1/en not_active Abandoned
- 2003-05-15 MX MXPA04010640A patent/MXPA04010640A/es active IP Right Grant
- 2003-05-15 WO PCT/EP2003/007443 patent/WO2003097164A1/en active Application Filing
- 2003-05-15 EP EP03738122A patent/EP1507573A1/en not_active Withdrawn
- 2003-05-15 NZ NZ535992A patent/NZ535992A/en not_active IP Right Cessation
- 2003-05-15 JP JP2004505157A patent/JP4773719B2/ja not_active Expired - Fee Related
- 2003-05-15 OA OA1200400307A patent/OA12819A/en unknown
- 2003-05-15 BR BR0310026-0A patent/BR0310026A/pt not_active IP Right Cessation
- 2003-05-16 US US10/439,827 patent/US20040014694A1/en not_active Abandoned
- 2003-05-16 MY MYPI20031829A patent/MY146533A/en unknown
- 2003-05-16 UY UY27812A patent/UY27812A1/es not_active Application Discontinuation
- 2003-05-16 PA PA20038574001A patent/PA8574001A1/es unknown
- 2003-05-16 TW TW092113275A patent/TWI374741B/zh not_active IP Right Cessation
-
2004
- 2004-10-21 ZA ZA2004/08549A patent/ZA200408549B/en unknown
- 2004-11-03 MA MA27924A patent/MA27417A1/fr unknown
- 2004-11-11 TN TNP2004000217A patent/TNSN04217A1/en unknown
- 2004-11-16 EC EC2004005433A patent/ECSP045433A/es unknown
- 2004-11-16 HR HR20041072A patent/HRPK20041072B3/xx not_active IP Right Cessation
- 2004-11-17 CR CR7575A patent/CR7575A/es unknown
- 2004-12-08 NO NO20045370A patent/NO20045370L/no not_active Application Discontinuation
-
2007
- 2007-06-28 US US11/769,859 patent/US20070265213A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200408549B (en) | 2006-01-25 |
| HRPK20041072B3 (en) | 2007-07-31 |
| MA27417A1 (fr) | 2005-07-01 |
| AU2003244646B2 (en) | 2008-08-07 |
| TWI374741B (en) | 2012-10-21 |
| US20070265213A1 (en) | 2007-11-15 |
| PA8574001A1 (es) | 2003-12-19 |
| WO2003097164A1 (en) | 2003-11-27 |
| NO20045370L (no) | 2004-12-08 |
| UA81628C2 (ru) | 2008-01-25 |
| ME00055B (me) | 2010-10-10 |
| MY146533A (en) | 2012-08-15 |
| OA12819A (en) | 2006-07-10 |
| IL165214A0 (en) | 2005-12-18 |
| EP1507573A1 (en) | 2005-02-23 |
| KR20050000544A (ko) | 2005-01-05 |
| CA2486124A1 (en) | 2003-11-27 |
| RU2321396C2 (ru) | 2008-04-10 |
| ECSP045433A (es) | 2005-01-03 |
| TNSN04217A1 (en) | 2007-03-12 |
| JP4773719B2 (ja) | 2011-09-14 |
| RS96304A (en) | 2006-10-27 |
| MXPA04010640A (es) | 2005-08-16 |
| UY27812A1 (es) | 2003-11-28 |
| CR7575A (es) | 2006-05-10 |
| JP2005529925A (ja) | 2005-10-06 |
| CN1652845A (zh) | 2005-08-10 |
| BR0310026A (pt) | 2005-02-15 |
| HRP20041072A2 (en) | 2005-06-30 |
| MEP16308A (en) | 2010-06-10 |
| NZ535992A (en) | 2008-11-28 |
| TW200407152A (en) | 2004-05-16 |
| US20040014694A1 (en) | 2004-01-22 |
| AU2003244646A1 (en) | 2003-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004136984A (ru) | Применение доцетаксела/доксорубицина/циклофосфамида во вспомогательной терапии рака молочной железы и яичников | |
| RU2008130963A (ru) | Лечение метастатического рака молочной железы | |
| MXPA03010121A (es) | Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales. | |
| RU2016102158A (ru) | Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака | |
| HK1104968A1 (en) | Use of immunomodulatory compounds in the manufacture of a medicament for the treatment and management of cancers and other diseases, and compositions thereof | |
| RU2008122358A (ru) | Лекарственные формы, содержащие ag013736 | |
| BRPI0518250A2 (pt) | tratamentos anticÂncer | |
| NO20032027L (no) | Effektive antitumorbehandlinger | |
| RU2014130874A (ru) | Схема лечения рака молочной железы с использованием нератиниба | |
| TNSN07294A1 (en) | Treatment of metastasized tumors | |
| RU2014137190A (ru) | Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение | |
| JP2015507020A5 (ru) | ||
| RU2009127775A (ru) | Способ введения пегилированного липосомального доксорубицина | |
| MX2009003532A (es) | Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina. | |
| CA2435921A1 (en) | Method of cancer therapy | |
| WO2005014032A3 (en) | Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite | |
| IL158058A (en) | Combination of a taxane and a cyclin-dependent kinase inhibitor | |
| RU2006122136A (ru) | Способ комбинированного лечения местно-распространенных форм рака шейки матки | |
| ES2211374T1 (es) | Dosificacion metronomica de taxanos para inhibir el crecimiento tumoral. | |
| TW200501967A (en) | Nemorubicin for use in the preparation of a medicament for liver disease | |
| RU2007115500A (ru) | Способ комбинированного лечения рака легкого iii стадии | |
| TH102680A (th) | การใช้โดซีแทกเซล/ดอกโซรูบิซิน/ไซโคลฟอสฟาไมด์ ในการรักษาแบบเสริม | |
| RU2001129201A (ru) | Способ лечения хронического травматического остеомиелита, осложненного гнойно-воспалительным процессом в околочелюстных мягких тканях | |
| RU2021115204A (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| MXPA05002465A (es) | Tratamiento del cancer de mama metastatico con antraciclinas y taxanos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20170516 |